Harmony Biosciences Reiterates 2026 Wakix Revenue Guidance
Harmony Biosciences reiterated its 2026 Wakix net revenue guidance of $1.0 billion to $1.04 billion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Harmony Biosciences Sets CEO Transition, Reiterates 2026 WAKIX Guidance
Peter Anastasiou will become CEO on Jan. 1, 2027, as Jeffrey M. Dayno retires Dec. 31, 2026. The company reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and expects BP-205 MAD data in Q4 2026.